Literature DB >> 19892322

Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease.

Anthony L Hinrichs1, Mark A Mintun, Denise Head, Anne M Fagan, David M Holtzman, John C Morris, Alison M Goate.   

Abstract

BACKGROUND: To date, all known Alzheimer's disease genes influence amyloid beta (Abeta). Imaging of Abeta deposition in the human brain using Pittsburgh Compound B (PIB) offers the possibility of using cortical PIB binding as a quantitative endophenotype for genetic studies of late-onset Alzheimer's disease (LOAD).
METHODS: Heritability of Abeta deposition was determined using 82 elderly siblings from 35 families. Correlation with other Abeta related traits was determined using an unrelated sample of 112 individuals. For both samples, apolipoprotein E (APOE) epsilon4 was genotyped and positron emission tomography imaging was performed using the PIB ligand. Mean cortical binding potential (MCBP) was computed from several regions of interest.
RESULTS: MCBP has a high heritability (.61, p = .043). Furthermore, 74% of the heritable component cannot be explained by APOE epsilon4 genotype. The unrelated sample reveals that a third of the variance of MCBP cannot be predicted by other biological traits, including cerebrospinal fluid (CSF) amyloid beta 42 (Abeta42) levels.
CONCLUSIONS: These findings demonstrate that MCBP is a genetic trait and that other more easily measured Abeta related traits such as CSF Abeta42 do not fully explain the variance in MCBP. Thus, MCBP is a useful trait for large-scale genetic studies of LOAD. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19892322      PMCID: PMC2866645          DOI: 10.1016/j.biopsych.2009.09.012

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  19 in total

1.  [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.

Authors:  M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

2.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

3.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

5.  Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer disease pedigrees.

Authors:  E W Daw; S C Heath; E M Wijsman
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

6.  A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume.

Authors:  Randy L Buckner; Denise Head; Jamie Parker; Anthony F Fotenos; Daniel Marcus; John C Morris; Abraham Z Snyder
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

7.  Brief screening tests versus clinical staging in senile dementia of the Alzheimer type.

Authors:  P B Davis; J C Morris; E Grant
Journal:  J Am Geriatr Soc       Date:  1990-02       Impact factor: 5.562

8.  Validation of a short Orientation-Memory-Concentration Test of cognitive impairment.

Authors:  R Katzman; T Brown; P Fuld; A Peck; R Schechter; H Schimmel
Journal:  Am J Psychiatry       Date:  1983-06       Impact factor: 18.112

Review 9.  Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.

Authors:  M J de Leon; L Mosconi; K Blennow; S DeSanti; R Zinkowski; P D Mehta; D Pratico; W Tsui; L A Saint Louis; L Sobanska; M Brys; Y Li; K Rich; J Rinne; H Rusinek
Journal:  Ann N Y Acad Sci       Date:  2007-02       Impact factor: 5.691

10.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Authors:  D Galasko; L Chang; R Motter; C M Clark; J Kaye; D Knopman; R Thomas; D Kholodenko; D Schenk; I Lieberburg; B Miller; R Green; R Basherad; L Kertiles; M A Boss; P Seubert
Journal:  Arch Neurol       Date:  1998-07
View more
  13 in total

1.  Finding risk in all the right places.

Authors:  Andrew B Singleton
Journal:  Neuron       Date:  2013-04-24       Impact factor: 17.173

Review 2.  Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.

Authors:  Marine Fouquet; Florent L Besson; Julie Gonneaud; Renaud La Joie; Gaël Chételat
Journal:  Neuropsychol Rev       Date:  2014-08-22       Impact factor: 7.444

Review 3.  PET amyloid-beta imaging in preclinical Alzheimer's disease.

Authors:  Andrei G Vlassenko; Tammie L S Benzinger; John C Morris
Journal:  Biochim Biophys Acta       Date:  2011-11-12

Review 4.  Alzheimer's disease: the challenge of the second century.

Authors:  David M Holtzman; John C Morris; Alison M Goate
Journal:  Sci Transl Med       Date:  2011-04-06       Impact factor: 17.956

Review 5.  Recent advances in imaging Alzheimer's disease.

Authors:  Meredith N Braskie; Arthur W Toga; Paul M Thompson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 6.  Molecular and cellular pathophysiology of preclinical Alzheimer's disease.

Authors:  Elliott J Mufson; Milos D Ikonomovic; Scott E Counts; Sylvia E Perez; Michael Malek-Ahmadi; Stephen W Scheff; Stephen D Ginsberg
Journal:  Behav Brain Res       Date:  2016-05-13       Impact factor: 3.332

7.  Individual estimates of age at detectable amyloid onset for risk factor assessment.

Authors:  Murat Bilgel; Yang An; Yun Zhou; Dean F Wong; Jerry L Prince; Luigi Ferrucci; Susan M Resnick
Journal:  Alzheimers Dement       Date:  2015-11-14       Impact factor: 21.566

8.  Using biomarkers to improve detection of Alzheimer's disease.

Authors:  Milton C Biagioni; James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2011-04

9.  Neuroimaging measures as endophenotypes in Alzheimer's disease.

Authors:  Meredith N Braskie; John M Ringman; Paul M Thompson
Journal:  Int J Alzheimers Dis       Date:  2011-03-31

10.  A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.

Authors:  Agneta Nordberg; Stephen F Carter; Juha Rinne; Alexander Drzezga; David J Brooks; Rik Vandenberghe; Daniela Perani; Anton Forsberg; Bengt Långström; Noora Scheinin; Mira Karrasch; Kjell Någren; Timo Grimmer; Isabelle Miederer; Paul Edison; Aren Okello; Koen Van Laere; Natalie Nelissen; Mathieu Vandenbulcke; Valentina Garibotto; Ove Almkvist; Elke Kalbe; Rainer Hinz; Karl Herholz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-08       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.